Dihydromyricetin as a novel anti-alcohol intoxication medication.
Level 5 - mechanism / opinion, no new human data
Preclinical animal and in vitro mechanistic study
PubMed 22219299 · doi:10.1523/JNEUROSCI.4639-11.2012
What was done
Researchers investigated the effects of dihydromyricetin (DHM, 1 mg/kg i.p.) on acute alcohol intoxication, withdrawal signs (tolerance, anxiety, seizure susceptibility), and intermittent voluntary alcohol consumption in rats. In vitro experiments in cultured neurons and hippocampal tissue (1 μM DHM) assessed GABA(A) receptor potentiation, receptor plasticity, and α4 subunit expression. Radioligand binding assays evaluated competitive inhibition of [(3)H]flunitrazepam binding, and flumazenil (10 mg/kg in vivo; 10 μM in vitro) was tested as an antagonist.
What was found
DHM at 1 mg/kg counteracted acute alcohol intoxication, reduced withdrawal signs, and greatly reduced voluntary alcohol consumption in rats. In vitro, 1 μM DHM antagonized acute alcohol-induced GABA(A) receptor potentiation and blocked alcohol-induced increases in GABA(A) receptor α4 subunit expression. DHM competitively inhibited [(3)H]flunitrazepam binding at the benzodiazepine site with an IC50 of 4.36 μM. Behavioral and cellular effects of DHM were antagonized by flumazenil.
Why it matters
This study identifies DHM as a potential therapeutic candidate for alcohol use disorders, demonstrating a specific molecular target (GABA(A) receptor benzodiazepine sites) that modulates both intoxication and withdrawal behaviors in rodents.
Limits
The study was conducted entirely in rodent models and cell cultures; no human clinical trials or pharmacokinetic data in humans were reported. Specific sample sizes (n) for animal cohorts and cell assays were omitted in the abstract.
Cited by
- supports In rodents, dihydromyricetin (DHM) reduces alcohol intoxication, decreases signs of alcohol withdrawal, and reduces voluntary alcohol consumption via interactions with GABA receptors.